Asthma Patient Survey Study to Assess Asthma Effect and Medication in Finland - Full Text View

Sponsor:	AstraZeneca
Information provided by:	AstraZeneca
ClinicalTrials.gov Identifier:	NCT00681382

Purpose

This study was aimed at clarifying how the asthma medication is used in practice and how asthma affects everyday life. Total of 106 GPs were asked to recruit patients using inhaled steroid as maintenance treatment for asthma to take part in a telephone survey. Altogether 142 patients were interviewed.

Condition
Asthma

Study Type:	Observational
Study Design:	Observational Model: Case-Only Time Perspective: Cross-Sectional
Official Title:	INSPIRE Asthma Patient Survey to Clarify the Use of Asthma Medication and Effects of Asthma in Everyday Life in Finland

Resource links provided by NLM:

MedlinePlus related topics: Asthma

U.S. FDA Resources

Further study details as provided by AstraZeneca:

Primary Outcome Measures:

Patients perceptions about treatment of asthma, asthma medication and what are the most common triggers that cause exacerbations. [ Time Frame: Single occasion ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

How patients react to the first signs of worsening of asthma i.e. how they use asthma medication during stable phase and asthma exacerbation [ Time Frame: Single occasion ] [ Designated as safety issue: No ]
How asthma affects everyday life [ Time Frame: Single occasion ] [ Designated as safety issue: No ]

Enrollment:	142
Study Start Date:	October 2006
Study Completion Date:	April 2007
Primary Completion Date:	April 2007 (Final data collection date for primary outcome measure)

Groups/Cohorts
1 Asthma patients using inhaled steroids as maintenance treatment

Eligibility

Ages Eligible for Study:	18 Years to 70 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

Primary care clinic

Criteria

Inclusion Criteria:

Diagnosed persistent asthma
regular use of inhaled steroids and concomitant medication

Exclusion Criteria:

never been diagnosed COPD
seasonal asthma

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00681382

Sponsors and Collaborators

AstraZeneca

Investigators

Study Director:	Airi Puhakka	AstraZeneca Finland
Principal Investigator:	Jouni Hedman	South Karelia Central Hospital, Finland

More Information

No publications provided

Responsible Party:	Klaus Tamminen - MC Medical Director, AstraZeneca
ClinicalTrials.gov Identifier:	NCT00681382 History of Changes
Other Study ID Numbers:	NIS-RFI-SYM-2006/1
Study First Received:	May 19, 2008
Last Updated:	January 21, 2011
Health Authority:	Finland: Ethics Committee

Keywords provided by AstraZeneca:

Asthma
use of asthma medication
asthma control
telephone survey
patient's perception

Additional relevant MeSH terms:

Asthma
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases

Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases

ClinicalTrials.gov processed this record on February 09, 2012